International Journal of Medical and Pharmaceutical Research
2026, Volume-7, Issue 4 : 1295-1304
Research Article
Maternal and Fetal Outcomes in Hyperglycemia in Pregnancy
 ,
 ,
Received
June 20, 2026
Accepted
July 1, 2026
Published
July 17, 2026
Abstract

Background: Hyperglycemia in pregnancy (HIP), particularly gestational diabetes mellitus (GDM), is one of the most common metabolic disorders complicating pregnancy and is associated with increased maternal and neonatal morbidity. Poor glycemic control can lead to adverse maternal outcomes such as urinary tract infections, vaginal candidiasis, preeclampsia, polyhydramnios, preterm labor, and premature rupture of membranes (PROM), while fetal complications include macrosomia, respiratory distress syndrome, hyperbilirubinemia, and neonatal intensive care unit (NICU) admission. Early diagnosis and appropriate management are essential to improve pregnancy outcomes.

Objectives: To assess the maternal outcomes associated with hyperglycemia in pregnancy, including vaginal candidiasis, symptomatic urinary tract infection (UTI), PROM, preterm labor, polyhydramnios, and preeclampsia, and to evaluate fetal outcomes in terms of macrosomia, hyaline membrane disease, and hyperbilirubinemia.

Materials and Methods: A prospective observational study was conducted over 18 months among 95 pregnant women diagnosed with hyperglycemia in pregnancy attending the antenatal clinic at Dr. B. R. Ambedkar Medical College and Hospital. Women with singleton pregnancies up to 28 weeks' gestation and a 2-hour plasma glucose level >140 mg/dL following a 75-g oral glucose challenge test were included. Demographic, clinical, laboratory, obstetric, and neonatal data were collected and analyzed using SPSS version 21. Statistical significance was considered at p < 0.05.

Results: Among the 95 participants, 52.6% were older than 30 years. Vaginal delivery was observed in 54.7% of cases, while 45.3% underwent lower segment cesarean section. The most common maternal complications were vaginal candidiasis (36.8%) and urinary tract infection (23.2%), followed by polyhydramnios, preterm labor, PROM, and preeclampsia. Fetal complications included hyaline membrane disease (11.6%), hyperbilirubinemia (9.5%), and macrosomia (5.3%). Polyhydramnios demonstrated a statistically significant association with mean OGTT values (p = 0.009), whereas no significant associations were found between OGTT values and other maternal or fetal complications.

Conclusion: Hyperglycemia in pregnancy remains an important contributor to maternal and neonatal morbidity. Universal screening, early diagnosis, strict glycemic control, and multidisciplinary management can significantly reduce adverse pregnancy outcomes. Long-term follow-up of both mothers and offspring is essential to prevent future metabolic disorders and improve overall maternal and child health.

Keywords
INTRODUCTION

Hyperglycemia in pregnancy (HIP) is one of the most prevalent medical disorders complicating pregnancy and encompasses gestational diabetes mellitus (GDM) as well as diabetes first recognized during pregnancy. Gestational diabetes mellitus is defined as glucose intolerance with onset or first recognition during pregnancy and accounts for the majority of cases of hyperglycemia in pregnancy. The prevalence of GDM has increased globally due to rising maternal age, obesity, sedentary lifestyles, and changing dietary patterns. In India, the prevalence varies widely from 5% to 28%, depending on the population studied and the diagnostic criteria used.

 

Pregnancy is characterized by progressive insulin resistance, particularly during the second and third trimesters, mediated by placental hormones such as human placental lactogen, cortisol, progesterone, and prolactin. In women unable to compensate with increased pancreatic insulin secretion, hyperglycemia develops, leading to gestational diabetes mellitus. Maternal hyperglycemia increases the transfer of glucose across the placenta, stimulating fetal pancreatic insulin secretion. Fetal hyperinsulinemia contributes to excessive fetal growth, altered metabolic adaptation after birth, and several neonatal complications.

 

Hyperglycemia in pregnancy is associated with numerous maternal complications, including urinary tract infections, vaginal candidiasis, hypertensive disorders, polyhydramnios, preterm labor, premature rupture of membranes, increased operative deliveries, and postpartum metabolic dysfunction. Neonates born to mothers with GDM are at increased risk of macrosomia, birth trauma, respiratory distress syndrome (hyaline membrane disease), neonatal hypoglycemia, hyperbilirubinemia, electrolyte disturbances, NICU admission, and long-term risks of obesity and type 2 diabetes mellitus.

 

Timely screening, early diagnosis, appropriate nutritional therapy, lifestyle modification, glucose monitoring, and pharmacological treatment when required have been shown to significantly improve maternal and neonatal outcomes. Universal screening using the 75-g oral glucose tolerance test (OGTT), as recommended by the Diabetes in Pregnancy Study Group India (DIPSI), is considered particularly suitable in the Indian population because of the high prevalence of GDM and the feasibility of implementing a single-step diagnostic approach.

 

Despite advances in obstetric care, hyperglycemia in pregnancy continues to pose substantial challenges in developing countries. Evaluating maternal and fetal outcomes among women with hyperglycemia provides valuable information for optimizing antenatal management and reducing pregnancy-related complications. Therefore, the present prospective observational study was undertaken to assess the maternal and fetal outcomes associated with hyperglycemia in pregnancy and to determine the relationship between maternal glycemic status and adverse pregnancy outcomes.

 

OBJECTIVES

To assess the various maternal outcomes in hyperglycemia of pregnancy such as Vaginal candidiasis, Symptomatic UTI, PROM, Preterm labor, Polyhydramnios. Preeclampsia.

 

To assess the various fetal outcome in terms of Macrosomia, Hyaline membrane disease , Hyperbilirubinemia

 

MATERIALS AND METHODS

Study Duration: The study was done for a period of 18months

 

Source of Data: All pregnant females visiting antenatal clinic At Dr. BR Ambedkar Medical college and hospital during study period.

 

Study Design: This is a Prospective Observational Study done in 95 patients

 

Sample Size:

Where,

nis the sample size,

Zisthestatisticcorrespondingtolevelofconfidence, p is expected prevalence, and

d=desired precision

 

Inclusion criteria

  • Pregnancy withup to28weeks of gestation.
  • Singleton pregnancy
  • Subjects with blood glucose level>140mg/dl 2hrs after 75gms glucose challenge test

 

Exclusion criteria

  • Already known cases of diabetes
  • Women with multiple pregnancies
  • Women with chronic diseases such as chronic renal failure, liver diseases, HIV, other immune compromised status, haemoglobinopathies

 

Methods of  Data collection

Institutional Ethical Review Board approval was obtained prior to initiation of the study. All the patients fulfilling the inclusion criteria were included in the study after their consent of participating and willingness to undergo required investigations as a part of the study.

 

The data was captured in the case record form[CRF], that were broadly classified into

 

Demographic Characteristics: Name, age, sex, address, contact details, monthly income, languages known, occupation, educational level, rural/urban, religion.

Patient history–Medicalhistory, familyhistory, menstrualhistory, marital history, obstetric history, personal history on diet, appetite, sleep and habits was noted

Clinical symptoms–complaints if any were noted down.

Examination: general physical examination, vitals, systemic examination, oer Speculum examination was done

 

Investigations–Hb, totalcount, OGCT, urine routine and culture sensitivity and USG findings was noted.

 

STATISTICAL ANALYSIS

Data is analyzed using SPSS software version 21 and Excel. Categorical variables are given in the form of frequency table. Continuous variables are given in Mean ± SD/ Median (Min, Max) form. Normality was checked by Shapiro wilk test. If the data follows normality then Pearson test will be done, otherwise non-parametric test Spearman’s rho correlation test will be used. P-value less than or equal to 0.05 indicates statistical significance.

 

RESULTS

Our results have data of 95 participants

 

Table10: Age group of the Study Population

AgeGroup

Frequency

Percentage(%)

< 30YEARS

45

47.4

>30YEARS

50

52.6

Total

95

100.0

 

Fig6 : Age group of the Study Population

 

The age distribution of the study participants shows a fairly balanced split, with aslightly higher proportion of individuals aged over 30years. Specifically, 47.4%(n=45) of the Participants were under 30 years of age, while 52.6%(n=50) were over 30 years of age.

 

Table11: Gestational Score of the Study Population

Gestational Score

Frequency

Percentage(%)

 

 

 

GRAVIDA

1

28

29.5

2

18

18.9

3

25

26.3

4

24

25.3

 

 

 

PARA

0

23

24.2

1

29

30.5

2

24

25.3

3

19

20.0

 

 

 

LIVING

0

17

17.9

1

25

26.3

2

30

31.6

3

23

24.2

 

 

ABORTION

0

35

36.8

1

30

31.6

2

30

31.6

 

The gestational score data provides insight into the obstetric history of the participants. Among the gravida scores, most participants were either gravida 1 (29.5%) or gravida 3 (26.3%), with smaller yet significant portions being gravida 2 (18.9%) and gravida 4(25.3%),indicatingavariedreproductivehistory.Forthepara-scores,thehighestproportion had one previous delivery (30.5%), followed by those with two (25.3%), and 24.2% had never delivered (para 0), while 20% had three prior deliveries. Regarding living children, the largest group had two living children (31.6%), followed by one (26.3%) and three (24.2%), with 17.9% reporting no living children. In terms of abortion history, 36.8% of participants had no abortions, while 31.6% had experienced one or two each, reflecting a fairly even distribution among those with a history of abortion.

 

Table12: Socio-economic status of the Study Population

Socio-economicstatus

Frequency

Percentage(%)

High

28

29.5

Low

35

36.8

Middle

32

33.7

Total

95

100.0

 

Fig 7: Socio-economicst atus of the Study Population

 

The data on socio-economic status among the study participants shows a fairly balanced distribution across the three categories. A majority of participants belonged to the low socio-economic group (36.8%), followed closely by those in the middle class (33.7%). The high socio-economic group constituted 29.5% of the sample. This near-even spread suggests that the study encompasses a diverse population in terms of economic background, which may influence various health-related outcomes, including access to care, nutrition, and overall maternal and neonatal health.

 

Table13:Dietarypattern of the Study Population

Dietarypattern

Frequency

Percentage(%)

Non-Veg

55

57.9

Veg

40

42.1

Total

95

100.0

 

Fig8: Dietary pattern of the Study Population

 

The data on dietary patterns indicates that a majority of the participants (57.9%) consumed a non-vegetarian diet, while 42.1% followed a vegetarian diet. This distribution highlights a predominance of non-vegetarian dietary habits among the study population, which may have implications for nutritional status, especially in relation to protein and micronutrient intake factors that can influence maternal and fetal outcomes.

 

Table14: Mode of delivery among Study Population

Mode of Delivery

Frequency

Percentage(%)

LSCS

43

45.3

Vaginal

52

54.7

Total

95

100.0

 

The data on mode of delivery shows that 54.7% of the participants had a vaginal delivery, while 45.3% underwent lower segment cesarean section (LSCS). This relatively balanced distribution suggests a moderately high rate of cesarean deliveries, which could reflect underlying maternal or fetal indications, healthcare practices, or patient preferences within the studied population.

 

Table15: Various Maternal Conditions in the study population

Maternal Conditions

Frequency

Percentage(%)

Vaginal

Candidiasis

No

60

63.2

Yes

35

36.8

 

UTI

No

73

76.8

Yes

22

23.2

The data on maternal conditions indicates that the most commonly reported issue was vaginal candidiasis, affecting 36.8%of the participants, followed by urinary tract infections (UTIs)in 23.2%. Poly hydramnios was observed in 15.8%, and pre-term labor in 14.7% of cases. Less frequent conditions included premature rupture of membranes (PROM) at 11.6%, and pre-eclampsia, which was present in only 7.4% of the population. Overall, while the majority of mothers did not experience these complications, a significant portion faced infections or pregnancy-related issues, highlighting the importance of antenatal screening and timely intervention.

 

Fig9: Maternal conditions

 

Table16: Various Fetal Conditions in the study population

Fetal Conditions

Frequency

Percentage(%)

 

Macrosomia

No

90

94.7

Yes

5

5.3

Hyaline membrane disease

No

84

88.4

Yes

11

11.6

 

Hyperbilirubinemia

No

86

90.5

Yes

9

9.5

The data on fetal conditions shows that macrosomia was relatively uncommon, occurring in only               5.3%      of

cases.     Hyaline membrane            disease  was        noted     in            11.6%,   while  hyper bilirubinemia affected 9.5% of the newborns. The vast majority of fetuses did not exhibit these conditions, suggesting generally favorable neonatal outcomes in this cohort. However, the presence of respiratory and metabolic issues in a minority indicates the need for vigilant neonatal monitoring and care post-delivery.

 

Fig:10 Fetal condition

 

Table17: Mean OGTT Values v/s Maternal Conditions

Maternal Conditions

Mean

 

OGTT

Standard

 

Deviation

ANNOVATest

 

p-Value

 

VaginalCandidiasis

No

200.98

29.94

p =0.309

Yes

194.54

28.93

 

UTI

No

198.77

28.30

p =0.926

Yes

198.09

34.21

 

Fig:11 Mean OGTT Values v/s Maternal Conditions

 

The comparison of mean Oral Glucose Tolerance Test (OGTT) values across various  maternal condition sreveals that polyhydramnios showed a statistically significant association with OGTT levels (p = 0.009), with affected individuals having a lower mean OGTT value (180.40mg/dL) compared to those without the condition (202.03mg/dL). This couldindicate a potential glycemic influence on amniotic fluid volume. Other conditions like vaginal candidiasis, UTI, PROM, pre-eclampsia, and pre-term labor did not show statistically significant differences in OGTT values, as their p-values were all above 0.05. While variations in glucose levels exist across conditions, only the link with polyhydramnios reached statistical significance in this sample.

 

Table18: Mean OGTT Values v/s Fetal Conditions

 

Fetal Conditions

Mean OGTT

Standard Deviation

ANNOVA

Test p-Value

 

Macrosomia

No

199.39

28.58

p =0.279

Yes

184.60

46.07

Hyaline membrane

 

disease

No

199.75

28.89

p =0.302

Yes

189.91

34.71

 

Hyperbilirubinemia

No

197.51

28.79

p =0.265

Yes

209.11

36.61

 

Fig18:Mean OGTT Values v/s Fetal Conditions

 

The analysis of mean OGTT values in relation to fetal conditions indicates that none of the observed associations were statistically significant, as all p-values are above 0.05. Although variations in glucose tolerance were noted — such as lower OGTT levels in cases of macrosomia (184.60 mg/dL) compared to those without (199.39 mg/dL) and higher OGTT levels in neonates with hyperbilirubinemia (209.11 mg/dL vs 197.51 mg/dL) . These differences did not reach statistical significance.Similarly, for hyalinemembrane disease, the mean OGTT was slightly lower in affected neonates (189.91 mg/dL) compared to unaffected (199.75 mg/dL), but the difference was also not significant (p = 0.302). Overall, while some trends are visible, no strong statistical evidence links OGTT levels to these specific fetal outcomes in this dataset.

 

CONCLUSION

Diabetes remains a significant disease threatening pregnant women and their offspring. The metabolic characteristics of GDM women are mirrored by OGTT values at diagnosis, but are not associated with adverse pregnancy outcomes. Intensive management and a tailored treatment of GDM improve maternal-neonatal outcomes, regardless of diagnostic values distribution and pre-gestational metabolic characteristics. Women with a history of GD Maswellas of fspring exposed to maternal diabetes in utero should be a major area of focus for preventive medicine. Preventive measures against type2 diabetes mellitus should start during intrauterine period and continue through out life from early childhood. Since the only expenditure involved is a simple screening blood test, it is recommended that all patients be universally screened for GDM.

 

In conclusion, a short term intensive care gives a long term pay of fin the primary prevention of impaired glucose tolerance, diabetes and obesity in the of fspring, as preventive medicine starts before birth. The maternal health and fetal outcome depends upon the care by the committed team of dialectologists, obstetricians and neonatologists

 

REFERENCES

  1. CunninghamFG,LevenoKJ,BloomSL,DasheJS,HoffmanBL,CaseyBM,etal. Williams Obstetrics. 24th ed. United States: McGraw-Hill Education; 2014. pp1125-43.
  2. Seshiah V, Das AK, Balaji V, Joshi SR, Parikh MN, Gupta S. Gestational Diabetes Mellitus for Diabetes In Pregnancy Study Group (DIPSI). Journal of the Association of Physicians of India. 2006 Aug;54:622-8.
  3. Landon MB, Scott JR, Gabbe SG. Clinical Obstetrics and Gynaecology – Gestational Diabetes Mellitus. 7th ed. Philadelphia: Elsevier Health Sciences; 2016. pp888-919.
  4. SeshiahV,BalajiV, BalajiMS,SanjeeviCB,GreenA. GestationalDiabetesMellitus in India. J Assoc Physicians India. 2004;52:707-11.
  5. Mohan’s Diabetic Education Academy. Module II- Screening and Diagnosis of Gestational Diabetes mellitus. PHFI Public Health Foundation of India; 2013 Aug to Nov.
  6. Arjun G, Seshadri L, Ram U. A Practical Guide to Obstetrics – Cost-effective, evidence-based, safe care PG. Hyderabad: Orient Black Swan; 2013 Jan 1. pp102-22.
  7. Berger H, Crane J, Farine D. Screening for gestational diabetes mellitus. J Obstet Gynaecol Can. 2002 Nov;121.
  8. American Diabetes Association. Diagnosis and classification of diabetes mellitus.Diabetes Care. 2012;35(1):64-71.
Recommended Articles
Research Article Open Access
Anobservational Study on Impact of Maternal Body Mass Index on Maternal and Neonatal Outcome
2026, Volume-7, Issue 4 : 1305-1315
Research Article Open Access
A Comparative Study of Open Lichtenstein Repair and Laparoscopic Mesh Repair in Inguinal Hernia
2026, Volume-7, Issue 4 : 1331-1336
Research Article Open Access
Comparison of the Efficacy and Safety of Intrathecal Levobupivacaine with Clonidine Versus Hyperbaric Bupivacaine with Clonidine for Spinal Anaesthesia in Patients Undergoing Elective Lower Segment Caesarean Section (LSCS).
2026, Volume-7, Issue 4 : 1316-1324
Research Article Open Access
Effectiveness Of Glycopyrronium Plus Indacaterol Combination in Patients with Moderate to Severe Chronic Obstructive Pulmonary Disease
2026, Volume-7, Issue 4 : 1273-1277
International Journal of Medical and Pharmaceutical Research journal thumbnail
Volume-7, Issue 4
Citations
4 Views
1 Downloads
Share this article
License
Copyright (c) International Journal of Medical and Pharmaceutical Research
Creative Commons Attribution License Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.
All papers should be submitted electronically. All submitted manuscripts must be original work that is not under submission at another journal or under consideration for publication in another form, such as a monograph or chapter of a book. Authors of submitted papers are obligated not to submit their paper for publication elsewhere until an editorial decision is rendered on their submission. Further, authors of accepted papers are prohibited from publishing the results in other publications that appear before the paper is published in the Journal unless they receive approval for doing so from the Editor-In-Chief.
IJMPR open access articles are licensed under a Creative Commons Attribution-ShareAlike 4.0 International License. This license lets the audience to give appropriate credit, provide a link to the license, and indicate if changes were made and if they remix, transform, or build upon the material, they must distribute contributions under the same license as the original.
Logo
International Journal of Medical and Pharmaceutical Research
About Us
The International Journal of Medical and Pharmaceutical Research (IJMPR) is an EMBASE (Elsevier)–indexed, open-access journal for high-quality medical, pharmaceutical, and clinical research.
Follow Us
facebook twitter linkedin mendeley research-gate
© Copyright | International Journal of Medical and Pharmaceutical Research | All Rights Reserved